CHEBI:31943 - oxatomide

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name oxatomide
ChEBI ID CHEBI:31943
Definition A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C27H30N4O
Net Charge 0
Average Mass 426.564
Monoisotopic Mass 426.24196
InChI InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
InChIKey BAINIUMDFURPJM-UHFFFAOYSA-N
SMILES O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
Application(s): H1-receptor antagonist
H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agent
A drug used to treat allergic reactions.
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
geroprotector
Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing oxatomide (CHEBI:31943) has role anti-allergic agent (CHEBI:50857)
oxatomide (CHEBI:31943) has role anti-inflammatory agent (CHEBI:67079)
oxatomide (CHEBI:31943) has role geroprotector (CHEBI:176497)
oxatomide (CHEBI:31943) has role H1-receptor antagonist (CHEBI:37955)
oxatomide (CHEBI:31943) has role serotonergic antagonist (CHEBI:48279)
oxatomide (CHEBI:31943) is a N-alkylpiperazine (CHEBI:46845)
oxatomide (CHEBI:31943) is a benzimidazoles (CHEBI:22715)
oxatomide (CHEBI:31943) is a diarylmethane (CHEBI:51614)
IUPAC Name
1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-1,3-dihydro-2H-benzimidazol-2-one
INNs Sources
oxatomida WHO MedNet
oxatomide WHO MedNet
oxatomide WHO MedNet
oxatomidum WHO MedNet
Synonyms Sources
1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one ChEBI
KW-4354 ChemIDplus
R 35 443 DrugCentral
R 35,443 ChemIDplus
R 35443 ChemIDplus
Brand Names Sources
Celtect KEGG DRUG
Celtomide DrugCentral
Cenacert ChEBI
Cobiona ChEBI
Tinset ChemIDplus
Manual Xrefs Databases
2014 DrugCentral
4454 ChemSpider
D01773 KEGG DRUG
DB12877 DrugBank
HMDB0240225 HMDB
Oxatomide Wikipedia
WO9858924 Patent
View more database links
Registry Numbers Types Sources
4724760 Reaxys Registry Number Reaxys
60607-34-3 CAS Registry Number ChemIDplus
60607-34-3 CAS Registry Number NIST Chemistry WebBook
Citations Waiting for Citations Types Sources
10513346 PubMed citation Europe PMC
12095890 PubMed citation Europe PMC
12635496 PubMed citation Europe PMC
12804426 PubMed citation Europe PMC
14685044 PubMed citation Europe PMC
18348338 PubMed citation Europe PMC
22464080 PubMed citation Europe PMC
24134630 PubMed citation Europe PMC
24474428 PubMed citation Europe PMC
26463039 PubMed citation Europe PMC
33896411 PubMed citation Europe PMC
3447306 PubMed citation Europe PMC
6130032 PubMed citation Europe PMC
6130033 PubMed citation Europe PMC
6131021 PubMed citation Europe PMC
6138301 PubMed citation Europe PMC
6475104 PubMed citation Europe PMC
6986007 PubMed citation Europe PMC
7465684 PubMed citation Europe PMC
Last Modified
29 October 2021